Publications by authors named "Sara M Tinsley-Vance"
Introduction/background: An improved understanding of cancer-related cachexia and sarcopenia among patients with hematologic malignancies can improve their health outcomes. Patients with hematologic malignancies are affected by cancer-related cachexia and sarcopenia, but this aspect of their care is rarely studied. This review aims to increase awareness and knowledge of cancer-related cachexia and sarcopenia for patients with hematologic malignancies through a comprehensive synthesis of current research.
View Article and Find Full Text PDFAcute myeloid leukemia (AML) is a deadly cancer, especially for patients over 60 years of age who face the dilemma of choosing the best treatment during a time of crisis. Current research in the older AML population is focused on survival without addressing quality of life (QOL). Survival and QOL data are essential for patients to decide which treatment best aligns with their goals, whether for survival or improved QOL.
View Article and Find Full Text PDFObjectives: To conduct an integrative review of studies to identify disparities in quality of life (QOL), symptoms, and symptom burden between men and women diagnosed with hematologic malignancies.
Sample & Setting: 11 studies comprising 13,546 participants aged 18 years or older were included in the analysis. Studies were original peer-reviewed research published in English between January 2005 and December 2020.
Article Synopsis
- The Molecular International Prognostic Scoring System (IPSS-M) is a new model for assessing risk in patients with myelodysplastic syndromes (MDS) that incorporates genetic mutation data for better accuracy compared to previous systems like IPSS and IPSS-R.
- A large study involving 2,355 MDS patients confirmed the IPSS-M's effectiveness in predicting overall survival (OS), leukemia-free survival (LFS), and the risk of leukemic transformation.
- The model categorizes patients into six risk groups, showing significant differences in median survival times, which supports the potential of IPSS-M to enhance treatment decisions for MDS patients.
Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
Clin Lymphoma Myeloma Leuk
May 2023
Article Synopsis
- A study at Moffitt Cancer Center analyzed clinical and genomic data from 4580 patients with Myelodysplastic Syndromes (MDS), revealing that a majority (66%) of patients were men.
- Women with MDS were generally younger and showed different clinical features, such as lower hemoglobin levels and higher platelet counts, along with distinct genetic abnormalities and a higher incidence of therapy-related MDS compared to men.
- Despite a lower overall survival rate in men, women had better survival outcomes in lower-risk MDS cases and were more responsive to certain immunosuppressive treatments, highlighting the need for further research on the impact of biological sex in MDS.
Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
J Adv Pract Oncol
January 2023
Treatment options are limited for patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). The recent approval of luspatercept for the treatment of anemia associated with very low-to intermediate-risk MDS with ring sideroblasts (RS) or with myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis has provided adult patients and practitioners with a much-needed new therapeutic option. Luspatercept is a first-in-class erythroid maturation agent that exerts its effects on later stages of erythropoiesis.
View Article and Find Full Text PDF